Distinctive responsiveness to stromal signaling accompanies histologic grade programming of cancer cells

PLoS ONE

Volumn 6, Issue 5, 2011, Pages

  Luciani, Maria Gloria ^a   Seok, Junhee ^b   Sayeed, Aejaz ^a   Champion, Stacey ^a   Goodson, William H ^a   Jeffrey, Stefanie S ^b   Xiao, Wenzhong ^b   Mindrinos, Michael ^b   Davis, Ronald W ^b   Dairkee, Shanaz H ^a  

^a CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYTAMOXIFEN;

APOPTOSIS; ARTICLE; BREAST CANCER; BREAST EPITHELIUM; CANCER CELL; CANCER GRADING; CANCER INHIBITION; CANCER RELAPSE; CANCER RESISTANCE; CELL CYCLE PROGRESSION; CELL DEATH; CELL PROLIFERATION; CONTROLLED STUDY; FIBROBLAST; GENETIC TRANSCRIPTION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; INFLAMMATION; MAJOR CLINICAL STUDY; OXIDATIVE STRESS; PROGNOSIS; SIGNAL TRANSDUCTION; STROMA CELL; BREAST TUMOR; CELL CYCLE; FEMALE; GENE EXPRESSION PROFILING; GENETICS; METABOLISM; PATHOLOGY; PRECANCER; TUMOR CELL LINE;

BREAST NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; GENE EXPRESSION PROFILING; HUMANS; PRECANCEROUS CONDITIONS; SIGNAL TRANSDUCTION; STROMAL CELLS;

EID: 79956282369     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0020016     Document Type: Article

References (46)

1. Bissell MJ, Radisky D, (2001) Putting tumours in context. Nature Rev Cancer 1: 46-54.
2. Liotta LA, Kohn EC, (2001) The microenvironment of the tumour-host interface. Nature 411: 375-379.
3. Allinen M, Beroukhim R, Cai L, Brennan C, Lahti-Domenici J, et al. (2004) Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell 6: 17-32.
4. Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, et al. (2005) Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 121: 335-348.
5. Kang H, Watkins G, Parr C, Douglas-Jones A, Mansel RE, et al. (2005) Stromal cell derived factor-1: its influence on invasiveness and migration of breast cancer cells in vitro, and its association with prognosis and survival in human breast cancer. Breast Cancer Res 7: R402-410.
6. Kleer CG, Bloushtain-Qimron N, Chen YH, Carrasco D, Hu M, et al. (2008) Epithelial and stromal cathepsin K and CXCL14 expression in breast tumor progression. Clin Cancer Res 14: 5357-5367.
7. Augsten M, Hägglöf C, Olsson E, Stolz C, Tsagozis P, et al. (2009) CXCL14 is an autocrine growth factor for fibroblasts and acts as a multi-modal stimulator of prostate tumor growth. Proc Natl Acad Sci USA 106: 3414-3419.
8. Bhowmick NA, Chytil A, Plieth D, Gorska AE, Dumont N, et al. (2004) TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 303: 848-851.
9. Kalluri R, Zeisberg M, (2006) Fibroblasts in cancer. Nat Rev Cancer 6: 392-401.
10. Micke P, Kappert K, Ohshima M, Sundquist C, Scheidl S, et al. (2007) In situ identification of genes regulated specifically in fibroblasts of human basal cell carcinoma. J Invest Dermatol 127: 1516-1523.
11. Makretsov NA, Hayes M, Carter BA, Dabiri S, Gilks CB, et al. (2007) Stromal CD10 expression in invasive breast carcinoma correlates with poor prognosis, estrogen receptor negativity, and high grade. Mod Pathol 20: 84-89.
12. Paulsson J, Sjöblom T, Micke P, Pontén F, Landberg G, et al. (2009) Prognostic significance of stromal platelet-derived growth factor beta-receptor expression in human breast cancer. Am J Pathol 175: 334-341.
13. West RB, Nuyten DS, Subramanian S, Nielsen TO, Corless CL, et al. (2005) Determination of stromal signatures in breast carcinoma. PLoS Biol 3: e187.
14. Finak G, Bertos N, Pepin F, Sadekova S, Souleimanova M, et al. (2008) Stromal gene expression predicts clinical outcome in breast cancer. Nat Med 14: 518-527.
15. Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, et al. (2007) Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 449: 557-563.
16. Stuelten CH, Busch JI, Tang B, Flanders KC, Oshima A, et al. (2010) Transient tumor-fibroblast interactions increase tumor cell malignancy by a TGF-Beta mediated mechanism in a mouse xenograft model of breast cancer. PLoS One 5: e9832.
17. Bourhis Dong-Le X, Berthois Y, Millot G, Degeorges A, Sylvi M, et al. (1997) Effect of stromal and epithelial cells derived from normal and tumorous breast tissue on the proliferation of human breast cancer cell lines in co-culture. Int J Cancer 71: 42-48.
18. Wadlow RC, Wittner BS, Finley SA, Bergquist H, Upadhyay R, et al. (2009) Systems-level modeling of cancer-fibroblast interaction. PLoS One 4: e6888.
19. Camp JT, Elloumi F, Roman Perez E, Rein J, Stewart DA, et al. (2010) Interactions with Fibroblasts are Distinct in Basal-like and Luminal Breast Cancers. Mol Cancer Res Dec 3 [Epub ahead of print].
20. Hu M, Peluffo G, Chen H, Gelman R, Schnitt S, et al. (2009) Role of COX-2 in epithelial-stromal cell interactions and progression of ductal carcinoma in situ of the breast. Proc Natl Acad Sci U S A 106: 3372-3377.
21. Dairkee SH, Sayeed A, Luciani G, Champion S, Meng Z, et al. (2009) Immutable functional attributes of histologic grade revealed by context independent gene expression in primary breast cancer cells. Cancer Res 69: 7826-7834.
22. Loi S, Haibe-Kains B, Desmedt C, Lallemand F, Tutt AM, et al. (2007) Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol 25: 1239-1246.
23. Schmidt M, Böhm D, von Törne C, Steiner E, Puhl A, et al. (2008) The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res 68: 5405-5413.
24. Luo J, Solimini NL, Elledge SJ, (2009) Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 136: 823-837.
25. Hanahan D, Weinberg RA, (2000) The hallmarks of cancer. Cell 100: 57-70.
26. Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, et al. (2006) Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 98: 262-272, 2006.
27. Ivshina AV, George J, Senko O, Mow B, Putti TC, et al. (2006) Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Research 66: 10292-10301.
28. Wirapati P, Sotiriou C, Kunkel S, Farmer P, Pradervand S, et al. (2008) Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res 10: R65.
29. Cornil I, Theodorescu D, Man S, Herlyn M, Jambrosic J, et al. (1991) Fibroblast cell interactions with human melanoma cells affect tumor cell growth as a function of tumor progression. Proc Natl Acad Sci USA 88: 6028-6032.
30. Boyd NF, Guo H, Martin LJ, Sun L, Stone J, et al. (2007) Mammographic density and the risk and detection of breast cancer. N Engl J Med 356: 227-236.
31. Park CC, Rembert J, Chew K, Moore D, Kerlikowske K, (2009) High mammographic breast density is independent predictor of local but not distant recurrence after lumpectomy and radiotherapy for invasive breast cancer. Int J Radiat Oncol Biol Phys 73: 75-79.
32. Cardone A, Tolino A, Zarcone R, Borruto Caracciolo G, Tartaglia E, (1997) Prognostic value of desmoplastic reaction and lymphocytic infiltration in the management of breast cancer. Panminerva Med 39: 174-177.
33. McMillin DW, Delmore J, Weisberg E, Negri JM, Geer DC, et al. (2010) Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity. Nat Med 16: 483-489.
34. Saal LH, Johansson P, Holm K, Gruvberger-Saal SK, She QB, et al. (2007) Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc Natl Acad Sci USA 104: 7564-7569.
35. Alexe G, Dalgin GS, Scanfeld D, Tamayo P, Mesirov JP, et al. (2007) High expression of lymphocyte-associated genes in node-negative HER2+ breast cancers correlates with lower recurrence rates. Cancer Res 67: 10669-10676.
36. Rody A, Holtrich U, Pusztai L, Liedtke C, Gaetje R, et al. (2009) T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers. Breast Cancer Res 11: R15.
37. Teschendorff AE, Miremadi A, Pinder SE, Ellis IO, Caldas C, (2007) An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. Genome Biol 8: R157.
38. Ma XJ, Dahiya S, Richardson E, Erlander M, Sgroi DC, (2009) Gene expression profiling of the tumor microenvironment during breast cancer progression. Breast Cancer Res 11: R7.
39. Reuter JA, Ortiz-Urda S, Kretz M, Garcia J, Scholl FA, et al. (2009) Modeling inducible human tissue neoplasia identifies an extracellular matrix interaction network involved in cancer progression. Cancer Cell 15: 477-488.
40. Sørum R, Hofvind S, Skaane P, Haldorsen T, (2010) Trends in incidence of ductal carcinoma in situ: The effect of a population-based screening programme. Breast 19: 499-505.
41. Dairkee SH, Nicolau M, Sayeed A, Champion S, Ji Y, et al. (2007) Oxidative stress pathways are highlighted in an immortalization signature in breast cancer. Oncogene 26: 6269-6279.
42. Dairkee SH, Seok J, Champion S, Sayeed A, Mindrinos M, et al. (2008) Bisphenol A induces a profile of tumor aggressiveness in high-risk cells from breast cancer patients. Cancer Res 68: 2076-80.
43. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, et al. (2003) Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4: 249-64.
44. Smyth GK, (2004) Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Statistical Applications in Genetics and Molecular Biology 3: No. 1, Article 3.
45. Benjamin RS, Hochberg Y, (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B 57: 289-300.
46. Sayeed A, Meng Z, Luciani G, Chen L-C, Bennington JL, et al. (2010) Negative regulation of UCP2 by TGFβ signaling characterizes low and intermediate-grade primary breast cancer. Cell Death and Disease 1: e53 doi:10.1038/cddis.2010.30.